SBIR/STTR Research Award
Sensitive Detection of Urinary Biomarkers of Renal Injury
Award amount
$150,000Program and phase
SBIR · Phase IAward year
2011Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- H & N Instruments Inc
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PA10-050
- Topic code
- NIDDK
Research abstract
DESCRIPTION (provided by applicant): If successful, this program will result in an assay chip that collects, stabilizes, and accurately quantifies a suite of biomarkers indicative of renal injury. Its sensitivity and accuracy may enable it to detect slowlyoccurring renal damage. Its multianalyte capability could distinguish different mechanisms of renal damage. It should be adaptable to automated assays and hence usable in a clinical setting. PUBLIC HEALTH RELEVANCE: The need for an early diagnosisof renal injury is important for patients with renal disease, for those undergoing kidney transplantation, and for patients undergoing drug therapy, especially new drugs that may cause renal damage. Traditional biomarkers are not capable of detecting earlystages of renal damage. For this reason there is high interest and activity in the search for new biomarkers of renal damage. There is less activity in developing new assay formats that use new biomarkers. We propose to develop a such an assay. We proposedeveloping a diagnostic chip capable of collection, stabilization, and highly sensitive and accurate quantification of a suite of biomarkers indicative of renal damage.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)